Your AI-Trained Oncology Knowledge Connection!
Dr. Sylvia Asa, MD, PhD, pathologist with the Toronto General Hospital/Research Institute (UHN) and a professor at the University of Toronto, discusses genotyping and the role it can play in diagnosing and selecting targeted treatments for thyroid cancer.
Dr. Nicole O. Vietor presented a report assessing practice discordances related to previously published guidelines published from the American Thyroid Association and the American Association of Clinical Endocrinologists.
A phase III study shows noninferiority of accelerated partial breast irradiation as compared to conventional whole breast irradiation.
Minesh Mehta, MBChB, talks about the recently FDA-approved Optune used to treat newly diagnosed glioblastoma. The device utilizes alternating electric fields to inhibit tumor cell growth.
Patients in a lenvatinib treatment arm with radioiodine-refractory differentiated thyroid cancer and certain metastasis experienced a much better overall median progression-free survival compared with a placebo arm.
Patients who received hypofractionated radiation therapy did not demonstrate statistically significant differences in long-term outcomes compared with patients who received conventional radiation therapy, according to a study .
Everolimus demonstrated a 52% reduction in the risk of progression or death in patients with lung/gastrointestinal neuroendocrine tumors, improving progression-free survival by 7.1 months compared with placebo.
The future of somatostatin analogs for neuroendocrine tumors (NETs) includes potential advances on several fronts, according to a presentation at the NANETS' 2015 Neuroendocrine Tumor Symposium.
Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.
Results from NETTER-1 trial showed an unprecedented 79% reduction in the risk of progression or death with the radiopharmaceutical Lu-Dotatate compared with high-dose octreotide LAR (60 mg) in patients with progressive, metastatic midgut neuroendocrine tumors (NETs).
Jay Ciezki, MD, staff member of the Department of Radiation Oncology at Cleveland Clinic and Department of Cell Biology at Cleveland Clinic, talks about the potential advantages of utilizing Stereotactic Body Radiation Therapy in prostate cancer patients.
Hypofractionation, known as delivering higher doses of radiation in fewer fractions, appears to be feasible and non-inferior compared with conventional fractionated radiotherapy.
Flares of bone pain decreased significantly when the oral corticosteroid dexamethasone was added to radiation therapy in patients with metastatic cancer, according to a randomized, placebo-controlled trial.
Coordinating radiation therapy teams and palliative care teams based on patient reported outcomes from University of Virginia Health System improved outpatient symptom management and decreased end-of-life hospitalizations, as well as costs of care for patients with late-stage cancer.
Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.
Combining the chemotherapy streptozotocin with various mTOR inhibitors was found to effectively target tumors in preclinical studies for pancreatic neuroendocrine tumors (pNETs).
Treatment with capecitabine and temozolomide is an effective therapy for patients with metastatic pancreatic neuroendocrine tumors.
Jennifer Eads, MD, assistant professor of Medicine, senior clinical instructor of Medicine, Case Western University, reflects on the phase III RADIANT-4 study, which examined everolimus in advanced nonfunctional neuroendocrine tumors of lung or gastrointestinal origin.
The 2015 NANETS Annual Symposium begins October 15 and the theme focuses on a team perspective. Kari Brendtro, founder of NANETS, recently spoke with Targeted Oncology about some of this year's upcoming presentations.
When cetuximab (Erbitux) was added to chemotherapy, the risk of death was reduced by 44% for patients with advanced squamous non-small cell lung cancer (NSCLC) whose tumors test positive for EGFR gene amplification.
Osimertinib (AZD9291), the third-generation TKI, demonstrated a 71% objective response rate (ORR) in those with EGFR T790M-mutant non-small cell lung cancer (NSCLC), following resistance to frontline anti-EGFR therapy.
When bevacizumab (Avastin) was added to adjuvant chemotherapy, overall survival (OS) did not improve in patients with surgically resected early-stage non-small cell lung cancer (NSCLC)
Continued treatment with gefitinib (Iressa) beyond progression showed a trend toward better outcomes for those with T790M-negative non-small cell lung cancer (NSCLC).
For patients who have metastatic squamous non-small cell lung cancer (NSCLC) whose tumors were positive for EGFR copy number, as determined by the FISH analysis, survival tended to be better with the addition of necitumumab to their conventional chemotherapy.
Coexisting driver mutations within EGFR-mutant non-small cell lung cancer (NSCLC) could possibly contribute to primary resistance to EGFR-targeted therapy.
Nivolumab (Opdivo) and ipilimumab (Yervoy), a chemotherapy-free regimen, showed activity as a first-line therapy for patients who have advanced non-small cell lung cancer (NSCLC).
Daniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.
By adding bevacizumab (Avastin) to a standard chemotherapy doublet, the risk of death is reduced by 24%, with the risk of disease reducing by 39%, in patients who have malignant pleural mesothelioma (MPM).
The majority of patients under the age of 40 who have lung cancer had tumors with mutations that can be targeted with existing therapies.
